Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)


Vermersch P., Eralinna J., Nicholas R., Oreja-Guevara C., Siva A. , Van Wijmeersch B., ...More

Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum, Florida, United States Of America, 27 - 29 February 2020, vol.26, pp.32 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 26
  • City: Florida
  • Country: United States Of America
  • Page Numbers: pp.32